Serum concentrations of specific cartilage and bone molecules reflecting tissue turnover were measured in two well-defined patient groups with early rheumatoid arthritis with distinctly different disease outcome to see if early differences in their levels are prognostic of the rate of joint destruction. Compared with a matched normal population, increased concentrations of cartilage oligomeric matrix protein (COMP) were found in all patients who developed rapid hip joint destruction. In contrast, levels of a putative marker of cartilage aggrecan synthesis, the chondroitin sulfate epitope 846, were increased only in patients with slow joint destruction. Levels of bone sialoprotein (BSP) were increased in both groups, as were levels of the C-propeptide of type II procoliagen (CPU), a marker of collagen II synthesis.
Introduction
Rheumatoid arthritis (RA) is a disease characterized by destruction of joint structures such as articular cartilage and bone (1) . The pathogenetic mechanisms responsible for tissue destruction are not well understood (2) (3) (4) . Furthermore, it is not clear why joint destruction progresses very slowly in some patients and causes little tissue derangement, whereas in others extensive destruction occurs within a few years after disease onset (5, 6) . In recent years the knowledge of the basic structure of cartilage and bone has grown rapidly (7) (8) (9) (10) . Consequently, the possibilities of studying turnover in these tissues at the molecular level have increased. One approach is to quantify by immunoassay, tissue-specific matrix molecules released into synovial fluid and blood as a means of studying the turnover of matrix components in vivo (11) (12) (13) . Such studies may help reveal basic mechanisms involved in matrix destruction. They may also lead to the development of clinically useful tools for disease monitoring. A problem, when interpreting results of measurements of matrix macomolecules or fragments thereof in body fluids, is that it is not apparent whether the released material represents newly synthesized components or degradation products of "resident" molecules. Since degradation is ordinarily coupled to an attempt at repair the release of matrix molecules should reflect both aspects of matrix turnover. Some analytes may preferentially reflect degradation while others may predominantly indicate repair. By assaying several molecules in the same sample of body fluid it should become possible to investigate matrix synthesis and degradation in different tissues.
In a previous study of early RA we showed that serum concentrations of a cartilage oligomeric matrix protein (COMP)' are initially elevated in those patients who later develop extensive joint destruction ( 14) . This suggested that disease pathogenesis is characterized by abnormal turnover of this protein in these patients. We have now extended this study to studies of the cartilage proteoglycan aggrecan and type II collagen. We have also compared cartilage metabolism to that of bone by measuring the release of bone sialoprotein (BSP).
BSP is a bone-specific protein, produced by the osteoblast, with a molecular mass of 70-80 kD. It has a protein backbone of 33 ,600 M, as determined by sequence analysis (8) . The protein stimulates hydroxyapatite formation in vitro (15) . It binds tightly to hydroxyapatite and contains an RGD integrin binding sequence. It thus might serve as a cell adhesion molecule allowing cells to attach to the extracellular matrix (8) . Its synthesis is inhibited by 1,25-dihydroxyvitamine D3 but is stimulated by dexamethasone added to cultured osteoblastic cells or to cultured calvaria explants (8) . BSP is particularly enriched in the cartilage-bone interphase (16) . Synovial fluid levels of the protein are higher in RA patients with advanced joint destruction than in patients with well preserved joints ( 17 ) . COMP is a cartilage specific protein with the highest concentrations being found in articular cartilage (18) . Oligomeric COMP has a molecular mass of 524 kD, as determined by sedimentation equilibrium ultracentrifugation (18) . On SDS-PAGE the reduced protein has an apparent molecular mass of 100 kD, suggesting that the protein is composed of five subunits. This structure was confirmed by rotary shadowing where the protein appeared as a bouquet-like, five armed structure (19) . Cloning and sequence analysis subsequently showed that the COMP subunit corresponds to an 83-kD polypeptide which has sequence homology with the thrombospondins, but is a unique gene product (20) . Studies of circulating levels of COMP in relation to therapy suggest that this released COMP preferentially reflects matrix repair, but this hypothesis needs to be verified (T Saxne & D Heinegard, unpublished observation).
The C-propeptide of type II collagen (CPII) is released by the activity of a C-proteinase, as procollagen is incorporated into the forming fibril (9) . The rate of synthesis of type II collagen is directly proportional to the content of CPII in cartilage with a tl/2 of 15-20 h (F. Nelson and A. R. Poole, manuscript in preparation). The propeptide is released from cartilage and enters the circulation where it can be detected by a specific immunoassay (21) . Its presence in body fluids is therefore an indicator of cartilage collagen synthesis.
The chondroitin sulfate epitope of aggrecan recognized by the monoclonal antibody 846 is present in hardly detectable amounts in normal adult cartilages. Its content is greatest in fetal and neonatal cartilages (22) . The epitope is a putative biosynthetic marker, the epitope being present on the largest molecules, which show 100% aggregability with hyaluronan. Moreover, the epitope is increased in content in osteoarthritic cartilage (23) . Furthermore, preliminary in vitro studies indicate that the level of the epitope in cartilage is directly correlated with aggrecan biosynthesis (H. Jugessur and A. R. Poole, unpublished observations). Recent studies of patients with chronic RA have revealed that serum levels are frequently elevated but it shows the highest concentrations in synovial fluids of diseased joints (24) . The available evidence to date thus suggest that fragments of aggrecan bearing the 846 epitope reflect the degradation of recently/newly synthesized aggrecan molecules.
In the present study we describe that rapid erosive joint disease is characterized by differences in the presence of these cartilage molecules in serum. Moreover, these changes may be of value in understanding the pathogenesis of joint disease. Furthermore, measurement of COMP and epitope 846 may assist in identifying patients at risk for rapid joint destruction.
Methods

Patients and controls
The 18 patients, who all fulfilled the established American Rheumatism Association Criteria for RA, have been previously described (14, 25) . They were selected from a cohort of 150 patients with RA of recent onset monitored at the Department of Rheumatology in Lund (26) . Nine patients were identified, who within 0.5-4 yr after disease onset developed significant erosive disease of the hip joints (Table I ). All 9 patients required unilateral or bilateral hip arthroplasty after a median disease duration of 2.8 yr (range 1.2-6 yr). Disease onset was defined as the time of onset of joint symptoms according to history at the initial visit to the department. These patients also developed erosive changes in their hands and feet. Another group of 9 RA patients, but without rapidly progressive disease leading to clinical hip involvement matched for age, gender, and disease duration was chosen from the group of 150 patients for comparison ( Table I ). The patients were selected based on their clinical features before any analysis of tissuemarkers was performed. The groups are referred to as rapid erosive and slow erosive, respectively.
All patients in the rapid erosive group received non-steroidal antiinflammatory drugs (NSAIDs). They were given a median of 11 intraarticular glucocorticoid injections during the study period, but no injection was given before the first serum sampling. Six patients were treated with slow acting antirheumatic drugs (chloroquine, sodium aurothiomalate, Dpenicillamine or azathioprine). In the slow erosive group, 7 patients were given NSAIDs, 2 paracetamol, and 2 were treated with D-penicillamine. These patients received a median of three intraarticular glucocorticoid injections during the study period. No patient received systemic corticosteroid treatment during the study period. Cartilage and bone molecular markers were measured in 3-5 serum samples from each patient during a median period of 2.7 years (range 1.6-4.2 yr) starting with the sample obtained at the patient's first visit to the department. This sample was drawn after a median of 0.9 yr (range 0.2-2.1 yr) from disease onset. The control group comprised 18 healthy blood donors matched for age and gender of the patients. It included 10 females and 8 males with a median age of 56 yr, range 25-70 yr. Blood samples were collected into tubes without additives. The blood was allowed to clot for 2 h at room temperature and was then centrifuged and stored at -80°C.
Radiographic examination
Hands, wrists, and feet of the 18 RA patients were examined radiographically on study entry and 1 and 2 years later. The radiographs were graded by the same radiologist without knowledge of clinical data using the Larsen method modified according to Pettersson (27, 28) . This method is based on comparisons with standard radiographs, where 0 denotes a normal appearing joint and 5 the one with most advanced changes. A theoretical range of values for these joints is 0-200. The scores for the patient groups are shown in Table I . The radiographs of the hips of the patients in the aggressive group all showed advanced damage prior to surgery (Larsen grade 5). Radiographs of the hips of the patients in the slow erosive group were not available.
Immunoassays
COMP. The serum concentrations of COMP in the patient groups were those previously reported (14) . Serum concentrations of COMP in the blood donors were determined using the same enzyme-linked inhibition immunosorbent assay (ELISA) (14, 29) . Polyclonal antibodies raised in a rabbit against the bovine protein were used. Purified human COMP was used for coating the microtiter plates and standards of human COMP were included in each plate. In each plate, reference samples from serum pools were also included. The intra-assay variation is < 5% and the inter-assay variation is < 8%.
CPII. A solution phase inhibition RIA was used employing bovine CPII isolated from fetal cartilage as described previously (21 ) . It was radiolabeled with '25I-NaI (DuPont NEN, Boston, MA) using chloramine-T (21). A rabbit antiserum (R160) to bovine CPII prepared as described (21) 50 ,ul of pig antirabbit IgG serum (previously precipitated with 50% ammonium sulfate to partially purify immunoglobulins but not to concentrate them). After incubation for 2 h at room temperature, 2 ml RIA buffer were added before centrifugation at 1,800 g for 20 min. Supematants were aspirated and pellets were counted in a y counter. Polypropylene tubes (12 x 75 mm; Fisher Scientific, Montreal) were used throughout, since CPII binds to glass. Standards (100 p.l) were prepared using purified bovine CPII in one quarter strength extraction buffer.
A typical standard inhibition curve is shown in Fig. 1 a. The interassay percentage coefficient of variation for serum samples was 9.3±9.3 (mean±SD, n = 35) whereas the intraassay variation was 6.3±5.2 (n = 31). To investigate the recovery of CPII from serum, bovine CPII in the range 75-475 pg was added to serum and assayed.
Percentage recovery was 96.5±3.6 (mean±SD, n = 6). Assay of varying volumes of serum permitted a comparison of the inhibition curves with the inhibition produced by a standard bovine preparation. The results (Fig. 1, b (24) .
BSP. Concentrations were determined by inhibition ELISA (17) . Microtiter plates were coated with purified human BSP and an antiserum raised in a rabbit against human BSP was used as first antibody. A standard curve of dilutions of human BSP was included in each plate as well as reference samples from serum pools. The inter-and intraassay variations of the method are < 10%.
Analysis of erythrocyte sedimentation rate, C-reactive protein and hyaluronan Erythrocyte sedimentation rate (ESR) was determined according to Westergren and C-reactive protein (CRP) using immunoassay (30) . Hyaluronan (HA) was analyzed using a radiometric assay (Pharmacia HA test; Pharmacia Diagnostica, Uppsala, Sweden) (31) .
Statistical calculations
Differences between groups were calculated using Mann-Whitney's test for unpaired variables. Correlations were calculated using Spearman's correlation coefficient. P values < 0.05 were considered significant. creased before surgery (14) . The concentrations of the first samples assayed in both disease groups were significantly higher than those in the sera from the matched controls (Table  II) . First samples in the rapid erosive group showed significantly higher COMP concentrations than first samples in the slow erosive group (Table III) . CPII. The serum concentrations of CPII are shown in Fig.  3 . The concentrations in both patient groups were increased compared to the concentrations in the controls (Table II) for CPII levels in the first sample (Table III) . However, three patients in the group with rapid erosive disease had considerably more elevated levels. These three patients also had the highest initial COMP levels. The levels of CPII did not change over time. 846 epitope. The concentrations of the 846 epitope are shown in Fig. 4 . In contrast to the findings for COMP and CPII, levels were only elevated over the controls in those with slow erosive disease (Table II) . Interestingly, the serum levels in the group with rapid erosive disease were often in the lower end of the normal range or even below the range of normal controls, although this did not reach statistical significance for the first patient samples. There were significant differences between the two disease groups for first samples (Table III) 5. The levels were higher in both the patient groups than in the controls for first samples (Table II) . There was no difference between the patient groups for first samples ( (Table III) .
Correlations between serum concentrations of the different molecules and markers of inflammation. The CPII and COMP levels showed significant positive correlations (first sample of both groups) (Table IV HA and CPII with CRP and HA. In contrast, epitope 846 exhibited an inverse correlation with both CRP and ESR. No such correlations were seen for BSP.
Discussion
Current knowledge of the pathophysiology of tissue destruction and the macromolecular changes that occur in cartilage and bone in RA has been gained mainly from studies in vitro and of animal models (32) (33) (34) . The conclusions reached in such experiments do not necessarily apply to the human situation. Studies of tissue metabolism in vivo in humans are therefore needed to substantiate experimental data. Here we have used immunoassays for the quantification of cartilage and bone specific molecules which enter the circulation as part of tissue turnover in the hope that they may reflect changes in the metabolism of extracellular matrix in these tissues. We examined patients with early RA to elucidate whether those with rapid erosive joint disease exhibit differences in the circulating levels of these molecules compared to those that do not develop severe joint damage within the same time period. Albeit the number of patients analyzed was low, the results obtained should be representative, since patient selection was based on carefully defined clinical criteria with no knowledge of results from marker analyses. There were some marked differences. In addition to the previously described elevation of COMP in rapid erosive disease, the most conspicuous finding was that whereas the concentrations of the chondroitin sulfate 846 epitope present in aggrecan were high in the sera of patients with slow erosive disease, as we described elsewhere (24) , very low, often subnormal, levels were found in the group with rapid erosive disease. Since this epitope appears to be present on the largest aggrecan molecules, and likely those that are newly synthesized, it appears that the increased levels of the 846 epitope reflect increased aggrecan synthesis (23, 24) . Thus, increased levels of such marker analytes observed in serum may reflect an ability or at least an attempt to repair the damaged extracellular matrix. This is in accordance with higher levels in serum from those patients that do not develop such rapid joint destruction as seen in the rapid erosive group. Thus elevated serum levels of the 846 epitope in RA may be a favorable prognostic sign.
The very low, often subnormal, serum levels of the 846 epitope in patients with active joint destruction likewise may reflect inhibition of aggrecan synthesis. This could result from excessive production of cytokines as a component of the inflammatory erosive process. Both tumor necrosis factor a and interleukin-have been shown in vitro and in vivo to produce such effects (9) . The inverse correlation of 846 epitope with CRP and ESR, both indexes of inflammation, supports an indirect relationship between cartilage repair and inflammation. However, as no information on epitope stability is available we cannot rule out that the low concentrations in the patients with more severe disease are due to greater destruction of the epitope.
Serum keratan sulfate (KS) has recently been found to correlate with the severity of articular damage in RA (35). Furthermore, serum KS levels correlate inversely with levels of tumor necrosis factor a (36) . These findings resemble those presented here for the 846 epitope. However, the 846 epitope is located, in part at least, on distinct and different fragments to those bearing KS (H. Jugessur and A. R. Poole, unpublished observations). In the present patient groups we did not measure KS due to shortage of material, but we have measured core protein epitopes in the sera of these patients (14) . Levels of these epitopes did not differ between the groups and did not correlate with levels of the 846 epitope (r = 0.141). Since we have previously found a strong correlation between serum KS and serum concentrations of core protein epitopes in arthritis (37) Only one patient in the rapid erosive group had slightly increased levels of the 846 epitope in all samples. Interestingly, this patient also had the highest COMP levels. Her CPII and BSP levels were also among the highest in the group. We were, however, not able to detect any signs, symptoms or other characteristics distinguishing this patient from the others in the group. The serum concentrations of bone derived BSP were increased in both groups compared to levels in the controls, which is in line with previous observations in RA patients (17; T. Saxne and D. Heinega.rd unpublished). This is probably due to the generalized involvement of bone in RA with release of BSP from all bone including the vertebrae. Whether this involvement precedes or reflects the osteopenia commonly seen in this disease remains to be established. That the BSP concentrations did not differ between the patient groups, suggests that the influence of joint inflammation on the metabolism of the juxtaarticular bone of large joints of the rapidly destructive group may be too small to show against the background of disturbed generalized bone turnover and that these changes reflect more generalized alterations in bone metabolism, which we observed regardless of the progression of joint disease. Corticosteroid treatment is known to influence the bone metabolism. Therefore it is noteworthy that the increased BSP levels in both groups were present before any intraarticular corticosteroid injections had been given. Furthermore, there was no correlation between the incidence of corticosteroid injections and changes in serum BSP levels during the study. Notably, statistical comparisons for all markers were made on results of samples obtained before any intraarticular corticosteroid injections had been given. Thus, the differences reported for the cartilage markers appear not to be biased by such treatment.
This study represents a first attempt to use combined measurements of several tissue-specific skeletal components in sera of clinically well-defined patient groups with RA to investigate disease activity. This approach opens new avenues to the understanding of the complexity of the skeletal metabolism in arthritis and raises new questions. By combining the clinical characteristics and the marker data it may be possible to increase the knowledge of the basic pathophysiology of joint disease and to use this information in clinical settings, such as for prognostic purposes and in therapeutic studies.
These observations draw attention to the fact that the measurement of cartilage derived macromolecules may be of prognostic value in determining disease progression, specifically at the level of erosive joint destruction.
